C
Chengdu Maxvax Biotechnology
CDMO for plasmid DNA, mRNA, and proteins.
News
Open roles
Chengdu Maxvax Biotechnology in the Chengdu ecosystem
The Chengdu Maxvax Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- KPKorea Investment Partners
- SPSherpa Venture Partners
Hillhouse Capital
Series B and later11 investors entered at this stage
- FCFangshizhen Capital
IDG Capital- QFQianhai FOF
- XCXinshang Capital
- GQGF Qianhe
- GCGuohai Innovative CCI Capital
- SISherpa Investment
- GIGortune Investment
- CIChina Life Private Equity Investment
Shenzhen Capital Group- SMShanghai Hankang Private Equity Fund Management
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. “Other / undisclosed” is the 4.8% not attributed to a named shareholder. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
Patents
143 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Chengdu Maxvax Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

